Julio Rosenstock

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 100

Top Venues

Diabetes, obesity & metabolism

Diabetes care

Endocrine reviews

BMJ open diabetes research & care

This page only lists publications with an associated author ORCID identifier.

Publications

Ulagamadesan Venkatesan, Mu Yang, Shun Fu Lee, Kelley R H Branch, Stephano Del Prato, Carolyn Su Ping Lam, Renato D Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar
Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE-O trial. Diabetes, obesity & metabolism (2024)
Julio Rosenstock, Rattan Juneja, John M Beals, Julie S Moyers, Liza Ilag, Rory J McCrimmon
The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa. Endocrine reviews 45 (3) (2024)
Harpreet S Bajaj, Björg Ásbjörnsdóttir, Tanvir Johanning Bari, Kamilla Begtrup, Tina Vilsbøll, Julio Rosenstock
Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials. Diabetes, obesity & metabolism (2024)
Julio Rosenstock, Rattan Juneja, John M Beals, Julie S Moyers, Liza Ilag, Rory J McCrimmon
The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa. Endocrine reviews (2024)
Julio Rosenstock, Harpreet S Bajaj, Ildiko Lingvay, Simon R Heller
Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review. BMJ open diabetes research & care 12 (3) (2024)
Matthias Blüher, Julio Rosenstock, Josef Hoefler, Raymond Manuel, Anita M Hennige
Correction to: Dose-response effects on HbA 1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia (2024)
Richard M Bergenstal, Athena Philis-Tsimikas, Carol H Wysham, Molly C Carr, Juliana M Bue-Valleskey, Fady T Botros, Thomas Blevins, Julio Rosenstock
Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme. Diabetes, obesity & metabolism 26 (8) (2024)
Julio Rosenstock, Harpreet S Bajaj, Ildiko Lingvay, Simon R Heller
Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review. BMJ open diabetes research & care 12 (3) (2024)
Julio Rosenstock, Harpreet S Bajaj, Ildiko Lingvay, Simon R Heller
Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review. BMJ open diabetes research & care 12 (3) (2024)
Harpreet S Bajaj, Björg Ásbjörnsdóttir, Tanvir Johanning Bari, Kamilla Begtrup, Tina Vilsbøll, Julio Rosenstock
Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: Participant-level meta-analysis of the ONWARDS 1-5 trials. Diabetes, obesity & metabolism 26 (9) (2024)
Khawaja M Talha, Jennifer Green, Gerasimos Filippatos, Stuart Pocock, Faiez Zannad, Martina Brueckmann, Elke Schueler, Anne Pernille Ofstad, Joao Pedro Ferreira, Stefan D Anker, Javed Butler, Julio Rosenstock, Milton Packer
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis. Diabetes, obesity & metabolism 26 (7) (2024)
Julio Rosenstock, Rattan Juneja, John M Beals, Julie S Moyers, Liza Ilag, Rory J McCrimmon
The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa. Endocrine reviews 45 (3) (2024)
Julio Rosenstock, Rattan Juneja, John M Beals, Julie S Moyers, Liza Ilag, Rory J McCrimmon
The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa. Endocrine reviews 45 (3) (2024)
Richard M Bergenstal, Athena Philis-Tsimikas, Carol H Wysham, Molly C Carr, Juliana M Bue-Valleskey, Fady T Botros, Thomas Blevins, Julio Rosenstock
Once-weekly insulin efsitora alfa: Design and rationale for the QWINT phase 3 clinical development programme. Diabetes, obesity & metabolism (2024)
Julio Rosenstock, Harpreet S Bajaj, Ildiko Lingvay, Simon R Heller
Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review. BMJ open diabetes research & care 12 (3) (2024)
Julio Rosenstock, Rattan Juneja, John M Beals, Julie S Moyers, Liza Ilag, Rory J McCrimmon
The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa. Endocrine reviews (2024)
Khawaja M Talha, Jennifer Green, Gerasimos Filippatos, Stuart Pocock, Faiez Zannad, Martina Brueckmann, Elke Schueler, Anne Pernille Ofstad, Joao Pedro Ferreira, Stefan D Anker, Javed Butler, Julio Rosenstock, Milton Packer
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis. Diabetes, obesity & metabolism (2024)
Khawaja M Talha, Jennifer Green, Gerasimos Filippatos, Stuart Pocock, Faiez Zannad, Martina Brueckmann, Elke Schueler, Anne Pernille Ofstad, Joao Pedro Ferreira, Stefan D Anker, Javed Butler, Julio Rosenstock, Milton Packer
Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An EMPEROR-Pooled analysis. Diabetes, obesity & metabolism 26 (7) (2024)
Martin Haluzík, Mohammed E Al-Sofiani, Alice Y Y Cheng, Felipe Lauand, Lydie Melas-Melt, Julio Rosenstock
Time-in-range derived from self-measured blood glucose in people with type 2 diabetes advancing to iGlarLixi: A participant-level pooled analysis of three phase 3 LixiLan randomized controlled trials. Diabetes, obesity & metabolism (2024)
Julio Rosenstock, Rattan Juneja, John M Beals, Julie S Moyers, Liza Ilag, Rory J McCrimmon
The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa. Endocrine reviews 45 (3) (2024)
Hiddo J Lambers Heerspink, Ellen Apperloo, Melanie Davies, Dror Dicker, Kristian Kandler, Julio Rosenstock, Rasmus Sørrig, Jack Lawson, Niels Zeuthen, David Z I Cherney
Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials. Diabetes care (2023)
Ulagamadesan Venkatesan, Rajibul Mian, Chinthanie Ramasundarahettige, Kelley R H Branch, Stephano Del Prato, Carolyn Su Ping Lam, Renato D Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar
Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial. Diabetes, obesity & metabolism 26 (4) (2023)
Cyrus V Desouza, Julio Rosenstock, Takuji Kohzuma, Vivian A Fonseca
Glycated Albumin Correlates with Time-in-Range Better than HbA1c or Fructosamine. The Journal of clinical endocrinology and metabolism (2023)
Julio Rosenstock, Ahmed A Kolkailah, Darren K McGuire, Mark A Espeland, Michaela Mattheus, Egon Pfarr, Søren S Lund, Nikolaus Marx, null null
Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial. Diabetes, obesity & metabolism (2023)
Julio Rosenstock, Luis Vázquez, Stephano Del Prato, Denise Reis Franco, Govinda Weerakkody, Biyue Dai, Laura Fernández Landó, Brandon K Bergman, Angel Rodríguez
Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials. Diabetes care (2023)
Julio Rosenstock, Ahmed A Kolkailah, Darren K McGuire, Mark A Espeland, Michaela Mattheus, Egon Pfarr, Søren S Lund, Nikolaus Marx, null null
Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial. Diabetes, obesity & metabolism (2023)
Julio Rosenstock, Clare J Lee, Laura Fernández Landó, Minzhi Liu, Chrisanthi A Karanikas, Vivian T Thieu
Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4 weeks in the SURPASS-1 monotherapy trial. Diabetes, obesity & metabolism (2023)
Julio Rosenstock, Ahmed A Kolkailah, Darren K McGuire, Mark A Espeland, Michaela Mattheus, Egon Pfarr, Søren S Lund, Nikolaus Marx, null null
Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial. Diabetes, obesity & metabolism (2023)
David Z I Cherney, Eleuterio Ferrannini, Guillermo E Umpierrez, Anne L Peters, Julio Rosenstock, David R Powell, Michael J Davies, Phillip Banks, Rajiv Agarwal
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease. Diabetes, obesity & metabolism (2023)
Ulagamadesan Venkatesan, Rajibul Mian, Chinthanie Ramasundarahettige, Kelley R H Branch, Stephano Del Prato, Carolyn Su Ping Lam, Renato D Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar
Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial. Diabetes, obesity & metabolism (2023)
Priyadarshini Balasubramanian, Walter N Kernan, Kevin Navin Sheth, Anne Pernille Ofstad, Julio Rosenstock, Christoph Wanner, Bernard Zinman, Michaela Mattheus, Nikolaus Marx, Catherine M Viscoli
Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials. Stroke (2023)
Matthias Blüher, Julio Rosenstock, Josef Hoefler, Raymond Manuel, Anita M Hennige
Dose-response effects on HbA 1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia (2023)
Muhammad Shariq Usman, Melanie Davies, Michael E Hall, Subodh Verma, Stefan D Anker, Julio Rosenstock, Javed Butler
The cardiovascular effects of novel weight loss therapies. European heart journal (2023)
Julio Rosenstock, Bertrand Cariou, Johanna Eliasson, Guillaume Frappin, Margit S Kaltoft, Eduard Montanya, Filip K Krag Knop
Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies. Diabetes, obesity & metabolism (2023)
Ulagamadesan Venkatesan, Rajibul Mian, Chinthanie Ramasundarahettige, Kelley R H Branch, Stephano Del Prato, Carolyn Su Ping Lam, Renato D Lopes, Richard Pratley, Julio Rosenstock, Naveed Sattar
Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial. Diabetes, obesity & metabolism 26 (4) (2023)
Julio Rosenstock, Ahmed A Kolkailah, Darren K McGuire, Mark A Espeland, Michaela Mattheus, Egon Pfarr, Søren S Lund, Nikolaus Marx, null null
Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial. Diabetes, obesity & metabolism (2023)
Julio Rosenstock, Stephen C Bain, Amoolya Gowda, Esteban Jódar, Bo Liang, Ildiko Lingvay, Tomoyuki Nishida, Roberto Trevisan, Ofri Mosenzon, null null
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. The New England journal of medicine (2023)
David Z I Cherney, Eleuterio Ferrannini, Guillermo E Umpierrez, Anne L Peters, Julio Rosenstock, David R Powell, Michael J Davies, Phillip Banks, Rajiv Agarwal
Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes and Stage 3 Chronic Kidney Disease. Diabetes, obesity & metabolism (2023)
John P H Wilding, Rachel L Batterham, Melanie Jane Davies, Luc F Van Gaal, Kristian Kandler, Katerina Konakli, Ildiko Lingvay, Barbara M McGowan, Tugce Kalayci Oral, Julio Rosenstock, Thomas A Wadden, Sean Wharton, Koutaro Yokote, Robert F Kushner, null null
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, obesity & metabolism 24 (8) (2022)
Philip D Home, Rory J McCrimmon, Julio Rosenstock, Matthias Blüher, Katrin Pegelow, Lydie Melas-Melt, Khier Djaballah, Francesco Giorgino, null null
Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics. Diabetes, obesity & metabolism (2022)
Roy Eldor, Bruce H Francis, Alexander Fleming, Joel Neutel, Kenneth Homer, Miriam Kidron, Julio Rosenstock
Oral insulin (ORMD-0801) in type 2 diabetes mellitus: A dose-finding 12-week randomized placebo-controlled study. Diabetes, obesity & metabolism (2022)
Matthew C Riddle, null null, George L Bakris, Lawrence Blonde, Andrew J M Boulton, Jessica R Castle, Linda A DiMeglio, Linda Gonder-Frederick, Frank B Hu, Steven E Kahn, Sanjay Kaul, Robert Geoffrey Moses, Stephen S Rich, Julio Rosenstock, Elizabeth Selvin, Adrian Vella, Judith Wylie-Rosett
Editorial Cycles and Continuity of Diabetes Care. Diabetes care 45 (7) (2022)
Vanita R Aroda, Robert Bauer, Erik Christiansen, Martin Haluzík, Klaus Kallenbach, Eduard Montanya, Julio Rosenstock, Juris J Meier
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme. Diabetes, obesity & metabolism 24 (7) (2022)
Rory J McCrimmon, Philip Home, Alice Cheng, Francesco Giorgino, Vivian A Fonseca, Elisabeth Souhami, Agustina Alvarez, Pascaline Picard, Julio Rosenstock
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial. Diabetes, obesity & metabolism 24 (12) (2022)
Juan Pablo Frias, JaeDuk Choi, Julio Rosenstock, Luiza Popescu, Elisabeth Niemoeller, Isabel Muehlen-Bartmer, SeungJae Baek
Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial. Diabetes care 45 (7) (2022)
Athena Philis-Tsimikas, Harpreet S Bajaj, Kamilla Begtrup, Roman Cailleteau, Amoolya Gowda, Ildiko Lingvay, Chantal Mathieu, David L Russell-Jones, Julio Rosenstock
Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes. Diabetes, obesity & metabolism (2022)
Julio Rosenstock
Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518. Diabetes care 44 (11) (2022)
William H Polonsky, Francesco Giorgino, Julio Rosenstock, Katherine Whitmire, Elisheva Lew, Mathieu Coudert, Agustina Alvarez, Charlie J Nicholls, Rory J McCrimmon
Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial. Diabetes, obesity & metabolism 24 (12) (2022)
Julio Rosenstock, Lawrence Blonde, Vanita R Aroda, Juan Pablo Frias, Elisabeth Souhami, Chen Ji, Elisabeth Niemoeller, Stephano Del Prato
Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening. Diabetes, obesity & metabolism 23 (6) (2021)
Julio Rosenstock, Rifat Emral, Leobardo Sauque-Reyna, Viswanathan Mohan, Carlos Trescolí, Saud Al Sifri, Nebojsa Lalic, Agustina Alvarez, Pascaline Picard, Mireille Bonnemaire, Nacima Demil, Rory J McCrimmon, null null
Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial. Diabetes care (2021)
Harpreet S Bajaj, Richard M Bergenstal, Andreas Christoffersen, Melanie J Davies, Amoolya Gowda, Joakim Isendahl, Ildiko Lingvay, Peter A Senior, Robert J Silver, Roberto Trevisan, Julio Rosenstock
Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. Diabetes care 44 (7) (2021)
Eleuterio Ferrannini, Julio Rosenstock
Response to Comment on Ferrannini and Rosenstock. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641-646. Diabetes care 44 (7) (2021)
Eleuterio Ferrannini, Julio Rosenstock
Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes care 44 (3) (2021)
Geremia B Bolli, Alice Cheng, Bernard Charbonnel, Vanita R Aroda, Jukka Westerbacka, Zsolt Bosnyak, Emmanuelle Boëlle-Le Corfec, Julio Rosenstock
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial. Diabetes, obesity & metabolism 23 (7) (2021)
Melanie Jane Davies, Julio Rosenstock, Amar Ali, David L Russell-Jones, Elisabeth Souhami, Karen Palmer, Chen Ji, Elisabeth Niemoeller, Neil Skolnik
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial. Diabetes, obesity & metabolism 24 (1) (2021)
David Z I Cherney, Eleuterio Ferrannini, Guillermo E Umpierrez, Anne L Peters, Julio Rosenstock, Amy K Carroll, Pablo Lapuerta, Phillip Banks, Rajiv Agarwal
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. Diabetes, obesity & metabolism 23 (12) (2021)
Rory J McCrimmon, Saud Al Sifri, Rifat Emral, Viswanathan Mohan, Leobardo Sauque-Reyna, Carlos Trescolí, Nebojsa Lalic, Agustina Alvarez, Nacima Demil, Mathieu Coudert, Alka Shaunik, Mireille Bonnemaire, Julio Rosenstock, null null
Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial. Diabetes, obesity & metabolism 23 (6) (2021)
Fernando Gomez-Peralta, Ebaa Al-Ozairi, Edward B Jude, Xiaoying Li, Julio Rosenstock
Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide-1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes. Diabetes, obesity & metabolism 23 (7) (2021)
Lawrence Blonde, Julio Rosenstock, Juan Pablo Frias, Andreas L Birkenfeld, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Stephano Del Prato, Vanita R Aroda
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study. Diabetes care 44 (3) (2021)
Ildiko Lingvay, John B Buse, Edward Franek, Melissa V Hansen, Mette M Koefoed, Chantal Mathieu, Jeremy Pettus, Karolina Stachlewska, Julio Rosenstock
A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. Diabetes care 44 (7) (2021)
Mark E Cooper, Julio Rosenstock, Takashi Kadowaki, Yutaka Seino, Christoph Wanner, Sven Schnaidt, Douglas Clark, Odd Erik Johansen, null null
Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial. Diabetes, obesity & metabolism 22 (7) (2020)
Javed Butler, James L Januzzi, Julio Rosenstock
Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. Diabetes, obesity & metabolism 22 (8) (2020)
Julio Rosenstock, Francisco Javier Ampudia-Blasco, Robert Lubwama, Xuejun Victor Peng, Anders Boss, Lizheng Shi, Vivian A Fonseca
Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists. Diabetes, obesity & metabolism 22 (12) (2020)
Vlado Perkovic, Robert Toto, Mark E Cooper, Johannes F E Mann, Julio Rosenstock, Darren K McGuire, Steven E Kahn, Nikolaus Marx, John H Alexander, Bernard Zinman, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Maximillian von Eynatten, Jyothis T George, Odd Erik Johansen, Christoph Wanner, null null
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes care 43 (8) (2020)
Julio Rosenstock, Harpreet S Bajaj, Andrej Janez, Robert Silver, Kamilla Begtrup, Melissa Voigt Hansen, Ting Jia, Ronald M Goldenberg, null null
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. The New England journal of medicine 383 (22) (2020)
Stephano Del Prato, Juan Pablo Frias, Lawrence Blonde, Vanita R Aroda, Niam Shehadeh, Aramesh Saremi, Terry Dex, Elisabeth Niemoeller, Elisabeth Souhami, Minzhi Liu, Julio Rosenstock
Impact of disease duration and β-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial. Diabetes, obesity & metabolism 22 (9) (2020)
Ulagamadesan Venkatesan, Kelley Branch, Laura Heenan, Stephano Del Prato, Nardev S Khurmi, Carolyn S P Lam, Richard Pratley, Julio Rosenstock, Naveed Sattar
Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist. Diabetes, obesity & metabolism 23 (2) (2020)
Julio Rosenstock, Antonio Nino, Joseph Soffer, Lois Erskine, Andre Acusta, Jo Dole, Molly C Carr, Jason Mallory, Philip Home
Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes care 43 (10) (2020)
Martin Haluzík, Alice Cheng, Dirk Müller-Wieland, Jukka Westerbacka, Zsolt Bosnyak, Felipe Lauand, Lydie Melas-Melt, Janaka Karalliedde, Julio Rosenstock, Geremia B Bolli
Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial. Diabetes, obesity & metabolism 22 (8) (2020)
Mark A Espeland, Richard E Pratley, Julio Rosenstock, Takashi Kadowaki, Yutaka Seino, Bernard Zinman, Nikolaus Marx, Darren K McGuire, Knut Robert Andersen, Michaela Mattheus, Annett Keller, Maria Weber, Odd Erik Johansen
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial. Diabetes, obesity & metabolism 23 (2) (2020)
Vanita R Aroda, Julio Rosenstock, Yasuo Terauchi, Yuksel Altuntas, Nebojsa M Lalic, Enrique C Morales Villegas, Ole K Jeppesen, Erik Christiansen, Christin L Hertz, Martin Haluzík, null null
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes care 42 (9) (2019)
Darren K McGuire, Nikolaus Marx, Odd Erik Johansen, Silvio E Inzucchi, Julio Rosenstock, Jyothis T George
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later. Diabetes, obesity & metabolism 21 (5) (2019)
Venugopal Menon, A Michael Lincoff, Stephen J Nicholls, Susan Jasper, Kathy Wolski, Darren K McGuire, Cyrus R Mehta, Julio Rosenstock, Claudia Lopez, John Marcinak, Charlie Cao, Steven E Nissen, null null
Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial. Diabetes care 41 (12) (2019)
Geert Jan Biessels, Chloë Verhagen, Jolien Janssen, Esther van den Berg, Bernard Zinman, Julio Rosenstock, Jyothis T George, Anna Passera, Sven Schnaidt, Odd Erik Johansen, null null
Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial. Diabetes care 42 (10) (2019)
Helena W Rodbard, Julio Rosenstock, Luis H Canani, Chaicharn Deerochanawong, Janusz Gumprecht, Søren Østergaard Lindberg, Ildiko Lingvay, Anette Luther Søndergaard, Marianne Bach Treppendahl, Eduard Montanya, null null
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes care 42 (12) (2019)
Vanita R Aroda, Matthew S Capehorn, Louis Chaykin, Juan Pablo Frias, Nanna L Lausvig, Stanislava Macura, Jörg Lüdemann, Sten Madsbad, Julio Rosenstock, Omur Tabak, Sayeh Tadayon, Stephen C Bain
Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials. Diabetes, obesity & metabolism 22 (3) (2019)
Alice Y Y Cheng, Stewart Harris, Francesco Giorgino, Jochen Seufert, Robert Ritzel, Kamlesh Khunti F MedSci, Felipe Lauand, Lydie Melas-Melt, Jukka Westerbacka, Zsolt Bosnyak, Julio Rosenstock
Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study. Diabetes, obesity & metabolism 22 (3) (2019)
Yehuda Handelsman, Chantal Mathieu, Stephano Del Prato, Eva Johnsson, Raisa Kurlyandskaya, Nayyar Iqbal, Ricardo Garcia-Sanchez, Julio Rosenstock
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes, obesity & metabolism 21 (4) (2019)
Julio Rosenstock, Shira Perl, Eva Johnsson, Ricardo García-Sánchez, Stephan Jacob
Triple therapy with low-dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes. Diabetes, obesity & metabolism 21 (9) (2019)
Lawrence Blonde, Julio Rosenstock, Stephano Del Prato, Robert R Henry, Naim Shehadeh, Juan Pablo Frias, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Vanita R Aroda
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. Diabetes care 42 (11) (2019)
Bruce A Perkins, Julio Rosenstock, Jay S Skyler, Lori M B Laffel, David Z I Cherney, Chantal Mathieu, Christianne Pang, Richard Wood, Ona Kinduryte, Jyothis T George, Jan Marquard, Nima Soleymanlou
Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes. Diabetes care 42 (9) (2019)
Jeremy H Pettus, David D'Alessio, Juan Pablo Frias, Eric G Vajda, James D Pipkin, Julio Rosenstock, Gretchen Williamson, Miriam A Zangmeister, Lin Zhi, Keith B Marschke
Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study. Diabetes care 43 (1) (2019)
Thomas P A Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney, Paul Strumph
Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. Diabetes care 42 (5) (2019)
Julio Rosenstock, Christopher H Sorli, Michael E Trautmann, Cristóbal Morales, Ulrich Wendisch, George Dailey, Marcus Hompesch, In Young Choi, Jahoon Kang, John Stewart, Kun-Ho Yoon
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide. Diabetes care 42 (9) (2019)
Nikolaus Marx, Nikolaus Marx, Vlado Perkovic, Hans-Juergen Woerle, Uli C Broedl, Maximilian von Eynatten, Jyothis T George, Julio Rosenstock
Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point? Diabetes care 40 (9) (2018)
Cristian Guja, Juan Pablo Frias, Aniko Somogyi, Serge A Jabbour, Hui Wang, Elise Hardy, Julio Rosenstock
Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study. Diabetes, obesity & metabolism 20 (7) (2018)
William T Cefalu, Sanjay Kaul, Hertzel C Gerstein, Rury R Holman, Bernard Zinman, Jay S Skyler, Jennifer B Green, John B Buse, Catherine M Viscoli, Lawrence A Leiter, Itamar Raz, Julio Rosenstock, Matthew C Riddle
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum. Diabetes care 41 (1) (2018)
Julio Rosenstock, Jan Marquard, Lori M B Laffel, Dietmar Neubacher, Stefan Kaspers, David Z I Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou, Bruce A Perkins
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes care 41 (12) (2018)
Julio Rosenstock, Alice Cheng, Robert A Ritzel, Zsolt Bosnyak, Christine Devisme, Anna M G Cali, Jochen Sieber, Peter Stella, Xiangling Wang, Juan P Frías, Ronan Roussel, Geremia B Bolli
More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. Diabetes care 41 (10) (2018)
Stephano Del Prato, Julio Rosenstock, Ricardo Garcia-Sanchez, Nayyar Iqbal, Lars Hansen, Eva Johnsson, Hungta Chen, Chantal Mathieu
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin. Diabetes, obesity & metabolism 20 (6) (2018)
Martin Ridderstråle, Julio Rosenstock, Knut R Andersen, Hans J Woerle, Afshin Salsali, null null
Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial. Diabetes, obesity & metabolism 20 (12) (2018)
Julio Rosenstock, Yehuda Handelsman, Josep Vidal, F Javier Ampudia Blasco, Francesco Giorgino, Minzhi Liu, Riccardo Perfetti, Juris J Meier
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Diabetes, obesity & metabolism 20 (12) (2018)
Philip D Home, Raymond L H Lam, Wendy L Carofano, Gregory T Golm, Roy Eldor, Michael F Crutchlow, Michael C Marcos, Julio Rosenstock, Priscilla A Hollander, Baptist Gallwitz
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial. Diabetes, obesity & metabolism 20 (9) (2018)
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas P A Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta, Darren K McGuire, Anne L Peters, John Reed, Sangeeta Sawhney, Paul Strumph
Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. Diabetes care 41 (9) (2018)
Priscilla A Hollander, Wendy L Carofano, Raymond L H Lam, Gregory T Golm, Roy Eldor, Michael F Crutchlow, Michael C Marcos, Marc S Rendell, Philip D Home, Baptist Gallwitz, Julio Rosenstock
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial. Diabetes, obesity & metabolism 20 (9) (2018)
Robert R Henry, Julio Rosenstock, Douglas S Denham, Prakash Prabhakar, Lise Kjems, Michelle A Baron
Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study. Diabetes care 41 (3) (2018)
William T Cefalu, John B Buse, Jaakko Tuomilehto, G Alexander Fleming, Ele Ferrannini, Hertzel C Gerstein, Peter H Bennett, Ambady Ramachandran, Itamar Raz, Julio Rosenstock, Steven E Kahn
Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2016;39:1186-1201. Diabetes care 40 (2) (2018)
William M Steinberg, Julio Rosenstock, Thomas A Wadden, Morten Donsmark, Christine B Jensen, J Hans DeVries
Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. Diabetes care 40 (7) (2017)
Julio Rosenstock, John B Buse, Rehan Azeem, Prakash Prabhakar, Lise Kjems, Holly Huang, Michelle A Baron
Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial. Diabetes care 41 (2) (2017)
Priscilla A Hollander, Harold E Bays, Julio Rosenstock, Mary Ellen Frustaci, Albert Fung, Frank Vercruysse, Ngozi Erondu
Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. Diabetes care 40 (5) (2017)

Julio Rosenstock.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Julio Rosenstock